Funded Biotechnology Startups in Tel Aviv
The 17 most recent funding rounds for Tel Aviv-based biotechnology companies in this dataset span June 2020 through December 2024.
The 17 most recent funding rounds for Tel Aviv-based biotechnology companies in this dataset span June 2020 through December 2024. Round sizes range from Donisi Health's $200K grant (December 2021) to InspireMD's $114M raise (May 2023), with CytoReason's $80M Series B (July 2024) the largest explicitly labeled equity round shown. Seed activity is prominent — Newmoo, Protai, Pangea Biomed, Eleven Therapeutics, and Drill all raised at that stage across 2021–2024. Grant funding appears at the margins, with Azura Ophthalmics, SuperMeat, and Donisi Health each receiving grants between mid-2021 and late 2022.
The most recent closed round is Purple Biotech's $3M raise in December 2024. Multiple rounds carry undisclosed amounts — RedHill Biopharma's October 2024 transaction among them — and two companies (Senecio Robotics, ECOncrete) have no round type on record despite disclosed amounts. The dataset reflects a mix of therapeutics, computational biology (CytoReason, Protai), wound care (RedDress), and food biotech (SuperMeat).
Most recent rounds
17 shownRelated listings
Frequently asked
What are the largest disclosed funding rounds among these Tel Aviv biotech companies?
InspireMD leads with a $114M raise in May 2023 (round type undisclosed), followed by CytoReason's $80M Series B closed in July 2024. RedDress ($26M Series D, May 2023) and Nym ($25M Venture round, July 2021) round out the top four disclosed raises in this dataset.
Which companies here are at the earliest funding stages?
Five companies raised Seed rounds: Newmoo ($7M, May 2024), Protai ($12M, March 2023), Pangea Biomed ($5M, December 2022), Eleven Therapeutics ($22M, August 2022), and Drill ($1M, December 2021). Donisi Health received a $200K grant in December 2021, the smallest disclosed amount in the dataset.
How active has Tel Aviv biotech funding been in 2024?
Four rounds in this dataset closed in 2024: Purple Biotech ($3M, December), RedHill Biopharma (undisclosed, October), Chemomab ($10M, July), and CytoReason ($80M Series B, July). CytoReason's raise is the largest disclosed 2024 round shown.
Are there any explicitly labeled growth-stage rounds in this dataset?
Two rounds carry explicit growth-stage labels: CytoReason's Series B ($80M, July 2024) and RedDress's Series D ($26M, May 2023). The remaining labeled equity rounds are either Seed-stage or classified as Series Unknown or Venture – Series Unknown.
How many rounds in this dataset have undisclosed amounts?
Three companies — RedHill Biopharma (October 2024), Azura Ophthalmics (September 2022), and SuperMeat (June 2022) — show undisclosed amounts. Senecio Robotics and ECOncrete have no round type listed despite disclosed amounts of $12M and $5M respectively.
Which companies received non-dilutive grant funding?
Azura Ophthalmics, SuperMeat, and Donisi Health each received grants — all between June 2021 and September 2022. Donisi Health's grant ($200K, December 2021) is the only one with a disclosed value; the other two are listed as undisclosed.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.